๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for EGFR Mutation Positive Non-small Cell Lung Cancer

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy NCT07375316Phase 24 sites๐Ÿ“ Guangzhou๐Ÿ“ Meizhou๐Ÿ“ Shantou Guangdong Association of Clinical Trials ยท Tests: Osimertinib + Sacituzumab Tirumotecan, Osimertinib A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases NCT05033691NA1 site๐Ÿ“ Jerusalem Hadassah Medical Organization ยท Tests: Stereotactic surgery A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation NCT07231068Phase 1, Phase 25 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Guangzhou Henan Genuine Biotech Co., Ltd. ยท Tests: Dositinib mesylate tablets Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases NCT07304739Phase 23 sites๐Ÿ“ Cangzhou๐Ÿ“ Tianjin๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Furmonertinib, Intrathecal chemotherapy, Stereotactic radiotherapy A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer NCT06631989Phase 1, Phase 212 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Guangzhou Wayshine Biopharm, Inc. ยท Tests: WSD0922-FU Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma NCT07314216Phase 21 site๐Ÿ“ Changsha Hunan Cancer Hospital ยท Tests: Firmonertinib, Definitive Thoracic Radiotherapy Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients NCT06659458n/a1 site๐Ÿ“ Baton Rouge Our Lady of the Lake Hospital ยท Tests: blood draw, Gene sequencing Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Genmab ยท Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression NCT06269211Phase 22 sites๐Ÿ“ Guangzhou๐Ÿ“ Shanghai Ruijin Hospital ยท Tests: Toripalimab A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC NCT06951464Phase 21 site๐Ÿ“ Chengdu Sichuan University ยท Tests: BL-B01D1, Almonertinib A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases NCT06970639Phase 31 site๐Ÿ“ Guangdong Allist Pharmaceuticals, Inc. ยท Tests: Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplatin for injection, Pemetrexed Disodium for Injection, Osimโ€ฆ Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer NCT06755684Phase 21 site๐Ÿ“ Shanghai Peng Zhang ยท Tests: Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer NCT04951635Phase 31 site๐Ÿ“ Ji'nan Jiangsu Hansoh Pharmaceutical Co., Ltd. ยท Tests: Almonertinib, Placebo Almonertinib Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC NCT06709859Phase 21 site๐Ÿ“ Jinan Shandong Public Health Clinical Center ยท Tests: Afatinib plus chemotherapy as conversion treatment A Phase 1/1b Study of IAM1363 in HER2 Cancers NCT06253871Phase 153 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Aurora Iambic Therapeutics, Inc ยท Tests: IAM1363 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy NCT04853342Phase 31 site๐Ÿ“ Suzhou Allist Pharmaceuticals, Inc. ยท Tests: Drug: Furmonertinib 80 mg, Furmonertinib 80 mg placebo Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive NCT07063329Phase 1, Phase 22 sites๐Ÿ“ Zhengzhou๐Ÿ“ Shanghai Avistone Pharmaceutical๏ผˆNingbo๏ผ‰Co., LTD. ยท Tests: PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy, PLB1004 80mg/160mg/240mg oral once โ€ฆ A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer NCT05104788Phase 21 site๐Ÿ“ Beijing Peking University Cancer Hospital & Institute ยท Tests: Icotinib, Cisplatin, Carboplatin, Pemetrexed To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy NCT06192849Phase 21 site๐Ÿ“ Chengdu Juan LI, MD ยท Tests: Furmonertinib A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer NCT07538804Phase 1, Phase 25 sites๐Ÿ“ Fairfax๐Ÿ“ Guangzhou๐Ÿ“ Harbin Avistone Biotechnology Co., Ltd. ยท Tests: ANS02 Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study NCT07696832n/a1 site๐Ÿ“ Guangzhou Guangdong Association of Clinical Trials ยท Tests: Ivonescimab Injection Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer NCT06304441NA1 site๐Ÿ“ Huizhou Guangzhou Medical University ยท Tests: Osimertinib, Pemetrexed Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma NCT07622706Phase 21 site๐Ÿ“ Beijing Peking University Cancer Hospital & Institute ยท Tests: Firmonertinib 80mg qd oral for 8 weeks., Firmonertinib 160mg qd oral for 8 weeks., Firmonertinib 80mg qd oral for 16 weโ€ฆ The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC NCT06109558Phase 1, Phase 21 site๐Ÿ“ Changsha Hunan Province Tumor Hospital ยท Tests: LMV-12(HE003) A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site๐Ÿ“ Shanghai Shanghai Chest Hospital ยท Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy NCT05469022Phase 21 site๐Ÿ“ Seoul Konkuk University Medical Center ยท Tests: Neoadjuvant lazertinib Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT NCT05236946Phase 31 site๐Ÿ“ Mumbai Tata Memorial Hospital ยท Tests: Stereotactic radiosurgery/whole brain radiotherapy, Tyrosine kinase inhibitor Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification NCT07322783Phase 21 site๐Ÿ“ Qingdao Qingdao Central Hospital ยท Tests: โ€ข Drug: Savolitinib โ€ข Drug: Osimertinib Mesylate Tablets To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT05442060Phase 27 sites๐Ÿ“ Taipei๐Ÿ“ Taipei๐Ÿ“ Taoyuan OBI Pharma, Inc ยท Tests: 30 ฮผg OBI-833/100 ฮผg OBI-821, Erlotinib (150 mg daily) Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations NCT06041776Phase 33 sites๐Ÿ“ Beijing๐Ÿ“ Nanjing๐Ÿ“ Shanghai Betta Pharmaceuticals Co., Ltd. ยท Tests: Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy